Response to VAD regimen and stem cell collection
| . | Arm A HDM140/TBI (n = 140) . | Arm B HDM200 (n = 142) . | P . |
|---|---|---|---|
| Median no. of courses of VAD (range) | 4 (3-6) | 4 (3-6) | .11 |
| Response to VAD regimen | |||
| CR (%) | 8 (6) | 7 (5) | .97 |
| VGPR (%) | 18 (13) | 17 (12) | .96 |
| PR (%) | 81 (58) | 86 (61) | .73 |
| Stable disease (%) | 33 (23) | 32 (22) | .95 |
| Stem cell collection | |||
| G-CSF priming (%) | 107 (76) | 107 (75) | .94 |
| Stem cell factor + G-CSF (%) | 5 (4) | 6 (4) | .98 |
| Cyclophosphamide + G-CSF (%) | 28 (20) | 29 (21) | .95 |
| Median no. of CD34 (106/kg) infused (range) | 7.3 (0.7-164) | 5 (1.2-132) | .03 |
| . | Arm A HDM140/TBI (n = 140) . | Arm B HDM200 (n = 142) . | P . |
|---|---|---|---|
| Median no. of courses of VAD (range) | 4 (3-6) | 4 (3-6) | .11 |
| Response to VAD regimen | |||
| CR (%) | 8 (6) | 7 (5) | .97 |
| VGPR (%) | 18 (13) | 17 (12) | .96 |
| PR (%) | 81 (58) | 86 (61) | .73 |
| Stable disease (%) | 33 (23) | 32 (22) | .95 |
| Stem cell collection | |||
| G-CSF priming (%) | 107 (76) | 107 (75) | .94 |
| Stem cell factor + G-CSF (%) | 5 (4) | 6 (4) | .98 |
| Cyclophosphamide + G-CSF (%) | 28 (20) | 29 (21) | .95 |
| Median no. of CD34 (106/kg) infused (range) | 7.3 (0.7-164) | 5 (1.2-132) | .03 |